Lymphoid-specific helicase inhibits cervical cancer cells ferroptosis by promoting Nrf2 expression

PeerJ. 2023 Nov 28:11:e16451. doi: 10.7717/peerj.16451. eCollection 2023.

Abstract

Background: Cervical cancer is a major cause of morbidity and mortality in women worldwide. The underlying mechanisms of its progression are not well understood. In this study, we investigated the role of lymphoid-specific helicase (HELLS) in cervical cancer.

Methods: We measured HELLS expression in cervical cancer and assessed its function using gain- and loss-of-function experiments. Cell viability was measured using the Cell Counting Kit-8 (CCK8 ) assay, and cell proliferation was analyzed using colony formation and EdU assays.

Results: We found that HELLS was significantly increased in cervical cancer and that its overexpression promoted cell viability (P < 0.01) and colony formation (P < 0.001). In contrast, si-HELLS suppressed these effects. Moreover, HELLS overexpression inhibited cell death induced by the ferroptosis inducer erastin (P < 0.01). Mechanistically, we found that HELLS promoted cervical cancer proliferation by regulating nuclear factor erythroid 2-related factor 2 (Nrf2)-mediated ferroptosis.

Conclusion: Our data suggest that HELLS promotes cervical cancer proliferation by inhibiting Nrf2 expression. Therefore, HELLS knockdown may be an effective treatment for cervical cancer.

Keywords: Cervical cancer; Ferroptosis; Lymphoid-specific helicase; Nuclear factor erythroid 2-related factor 2.

MeSH terms

  • Cell Death
  • Cell Survival
  • Female
  • Ferroptosis*
  • Humans
  • NF-E2-Related Factor 2 / genetics
  • Uterine Cervical Neoplasms* / genetics

Substances

  • NF-E2-Related Factor 2

Grants and funding

The authors received no funding for this work.